Abstract:To the Editor: We read with great interest the recently published article by Broersen et al.1 This study demonstrated the significant association between hs-cTnT (high-sensitivity cardiac troponin T) in patients with mild-to-moderate first-ever ischemic stroke without dementia and high prevalence of cognitive impairment at baseline and during 3-year follow-up. Recently, there has been much interest in the association of elevated cTnT, a specific biomarker for myocardial injury, with cognitive impairment. The ARIC study (Atherosclerosis Risk in Communities) found that people in communities with elevated hs-cTnT at baseline had lower cognitive scores at baseline and increased risk of dementia hospitalization during follow-up.2 Coronary heart disease was also associated with accelerated cognitive decline.3 These studies show that subclinical myocardial injury may be associated with cognitive decline. For patients with mild-to-moderate first-ever ischemic stroke without dementia, similar results were found. These patients with elevated hs-cTnT at admission baseline had lower cognitive function scores and more significant cognitive impairment during follow-up. Authors proposed 3 possible underlying mechanisms for this result. First, heart disease may cause ischemic stroke. Second, stroke-heart syndrome impaired autonomic cardiac function with myocardial damage after stroke. Finally, common vascular risk factors may lead to damage of both organs simultaneously as small vessel disease. Although authors perfectly explained why patients with first-ever ischemic stroke have increased hs-cTnT, they did not explain why elevated hs-cTnT was associated with worse cognitive function at baseline and during follow-up. Unlike that in community populations, cognitive decline in patients with ischemic stroke may be influenced by more factors. For example, cardiogenic infarction may be larger and more acute and may cause severer cognitive deficiency. Patients with heart diseases may continuously shed small thrombus, which can result in brain damage and cognitive impairment. Heart failure and usage of beta-blockers may reduce the cardiac output, which can decrease the cerebral blood flow and cause white matter lesions.4 Another possible mechanism for elevated hs-cTnT in stroke patients with cognitive decline may be related to the shared risk factors. Elevated hs-cTnT levels in patients with stroke were associated with impaired cognitive function at baseline (RR, 1.66 [95% CI, 1.26– 2.17]). After adjusting for major vascular risk factors, the association became insignificant (RR, 1.20 [95% CI, 0.89–1.62]). Common vascular risk factors, such as age, sex, obesity, smoking, alcohol consumption, cysteinemia, hypertension, hyperlipidemia, and diabetes mellitus have been associated with cognitive impairments.

Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study

Low Serum Superoxide Dismutase is Associated with a High Risk of Cognitive Impairment after Mild Acute Ischemic Stroke

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

Low Hemoglobin Levels at Admission Are Independently Associated with Cognitive Impairment after Ischemic Stroke: a Multicenter, Population-Based Study

Plasma Soluble Suppression of Tumorigenicity 2 and Depression after Acute Ischemic Stroke

The association between plasma soluble triggering receptor expressed on myeloid cells 2 and cognitive impairment after acute ischemic stroke

Association of Cardiac Biomarkers in Combination with Cognitive Impairment after Acute Ischemic Stroke.

Elevated Serum Levels of Soluble ST2 Are Associated with Plaque Vulnerability in Patients with Non-ST-Elevation Acute Coronary Syndrome

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and <i>meta</i>-analysis

Decreased plasma Aβ levels were not associated with post‐stroke cognitive impairment: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers

Soluble TREM2 is associated with death and cardiovascular events after acute ischemic stroke: an observational study from CATIS

Plasma sDPP4 (Soluble Dipeptidyl Peptidase-4) and Cognitive Impairment After Noncardioembolic Acute Ischemic Stroke

Letter by Xu Et Al Regarding Article, "High-Sensitivity Cardiac Troponin T and Cognitive Function in Patients with Ischemic Stroke".

Plasma Endostatin Levels at Acute Phase of Ischemic Stroke Are Associated with Post-Stroke Cognitive Impairment

Association of Soluble Intercellular Adhesion Molecule 1 with Neurological Deterioration of Ischemic Stroke: the Chongqing Stroke Study.

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis

High Plasma Thrombomodulin Level is Associated with a Decreased Risk of Cognitive Impairment after Ischemic Stroke

Soluble ST2 Levels for Predicting the Presence and Severity of Metabolic Syndrome

Plasma Neuropeptide Y and Cognitive Impairment after Acute Ischemic Stroke.

Correlation of Plasma Soluble Suppression of Tumorigenicity-2 Level with the Severity and Stability of Coronary Atherosclerosis

Plasma Soluble Dipeptidyl Peptidase-4 and Risk of Major Cardiovascular Events After Ischemic Stroke: Secondary Analysis of China Antihypertensive Trial in Acute Ischemic Stroke (CATIS)